For central nervous system (CNS) innovation to matter, it has to reach the patients who need it. The pipeline has never been more promising, with scientific advances moving at pace — yet too many therapies still struggle to translate that promise into clinical, regulatory, payer, and commercial success. The challenge isn’t that the science is failing; it’s that critical value considerations are often brought in too late.
In Part One of a two-part series published in Drug Discovery Online, our own Ginger Johnson, SVP and Neuroscience Lead at Lumanity, explores how companies can connect the science to the realities of CNS drug development earlier. Here’s a look at some of the key themes from that conversation.
Read Part One of the two-part series:
Read Part One of the Article
"*" indicates required fields
